Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8573-8580

  Hu, Bin ^a   Yang, Hongmei ^a   Yang, Hongwei ^b  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Diagnosis; Meta analysis; Prostate cancer; Urine prostate cancer antigen 3

Indexed keywords

PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN;

ARTICLE; CANCER TEST; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC LIKELIHOOD RATIO; DIAGNOSTIC ODDS RATIO; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MALE; META ANALYSIS; PROSTATE CANCER; PROSTATE CANCER ANTIGEN 3 URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL CONCEPTS; SYSTEMATIC REVIEW; URINE LEVEL; URINE PROSTATE CANCER ANTIGEN 3 TEST; PROSTATIC NEOPLASMS; REFERENCE VALUE; URINE;

ANTIGENS, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84919836153     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2109-4     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–8.
4. Freedland SJ, Partin AW. Detecting prostate cancer with molecular markers: uPM3. Rev Urol. 2005;7:236–8.
5. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089–95.
6. Overmyer M. New PCA assay aids critical diagnostic decisions. Urology Times. July 1, 2006.
7. Marks LS, Fradet Y, Lim Deras I, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69:532–5.
8. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
10. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.
11. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;10:3–25.
12. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–60.
14. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21(9):1237–56.
15. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
16. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081–8.
17. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587–92.
18. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804–9.
19. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. PCA3 Urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology. 2009;73:363–8.
20. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer. 2009;115:3879–86.
21. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol. 2010;58:475–81.
22. Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate. 2010;70:1760–7.
23. Auprich M, Haese A, Walz J, Pummer K, De La Taille A, Graefen M, et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol. 2010;58:727–32.
24. Vlaeminck-Guillem V, Campos-Fernandes JL, Champetier D, Chikh K, Decaussin-Petrucci M, Devonec M, et al. Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience. Ann Biol Clin (Paris). 2011;69:31–9.
25. Ochiai A, Okihara K, Kamoi K, Iwata T, Kawauchi A, Miki T, et al. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol. 2011;18(3):200–5.
26. De La Taille A, Irani J, Graefen M, Chun F, De Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185:2119–25.
27. Ng CF, Chiu PKF, Lam NY, Yeung R, Chow J, Chan B. The role of urine prostate cancer antigen 3 mrna levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J. 2012;18:459–65.
28. Crawford ED, Rove KO, Trabulsi EJ, Qian JQ, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188:1726–31.
29. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res. 2013;33:553–8.
30. Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama SI, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 2013;111:928–33.
31. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
32. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804–18.
33. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112:1650–9.
34. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:11320–8.
35. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.
36. Lacetera V, Galosi AB, Cantoro U, et al. Transrectal ultrasound (TRUS) and TRUS-biopsy accuracy in potential candidates for PRIAS active surveillance protocol. Arch Ital Urol Androl. 2012;84:272–5.
37. Barbera M, Pepe P, Paola Q, Aragona F. PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients. Arch Ital Urol Androl. 2012;84:227–9.
38. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587–92.
39. Goode RR, Marshall SJ, Duff M, Chevli E, Chevli KK. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate. 2013;73:48–53.
40. de la Taille A, Irani J, Graefen M, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185:2119–25.
41. Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radio. 1979;14(2):109–21.